Eva M. Ciruelos

Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: April 16, 2026

HER2DX in early-stage HER2-positive breast cancer: a review of clinical utility.

Journal: ESMO open

Published: April 11, 2026

Tucatinib in patients with HER2-positive advanced/metastatic breast cancer: A systematic literature review of real-world evidence.

Journal: Breast (Edinburgh, Scotland)

Published: March 12, 2026

Primary results from EL1SSAR, a prospective phase IIIb study of first-line atezolizumab plus nab-paclitaxel therapy for patients with PD-L1-positive advanced triple-negative breast cancer.

Journal: Breast (Edinburgh, Scotland)

Published: March 11, 2026

Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 - metastatic breast cancer: A translational analysis of the GEICAM/2013-02 PEARL trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 10, 2026

Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer.

Journal: The New England journal of medicine

Published: January 28, 2026

Navigating first- and second-line treatment options in hormone receptor-positive HER2-negative advanced breast cancer.

Journal: The oncologist

Published: January 22, 2026

Navigating first- and second-line treatment options in HR+HER2-negative advanced breast cancer.

Journal: The oncologist

Published: January 22, 2026

Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer.

Journal: ESMO open

Published: January 16, 2026

Real-world clinical outcomes of intermediate-risk PAM50 (i-ROR) in HR+/HER2- early breast cancer and eligibility for adjuvant CDK4/6 inhibitors.

Journal: Breast cancer research and treatment

Published: December 22, 2025

Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: December 09, 2025

Analysis of UGT1A1 germline variants in patients with advanced breast cancer treated with trastuzumab-deruxtecan: results from the PROCURE Project.

Journal: ESMO open

Published: November 25, 2025

Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer.

Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer.

HER2DX in early-stage HER2-positive breast cancer: a review of clinical utility.

HER2DX in early-stage HER2-positive breast cancer: a review of clinical utility.

Tucatinib in patients with HER2-positive advanced/metastatic breast cancer: A systematic literature review of real-world evidence.

Tucatinib in patients with HER2-positive advanced/metastatic breast cancer: A systematic literature review of real-world evidence.

Primary results from EL1SSAR, a prospective phase IIIb study of first-line atezolizumab plus nab-paclitaxel therapy for patients with PD-L1-positive advanced triple-negative breast cancer.

Primary results from EL1SSAR, a prospective phase IIIb study of first-line atezolizumab plus nab-paclitaxel therapy for patients with PD-L1-positive advanced triple-negative breast cancer.

Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 - metastatic breast cancer: A translational analysis of the GEICAM/2013-02 PEARL trial.

Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 - metastatic breast cancer: A translational analysis of the GEICAM/2013-02 PEARL trial.

Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer.

Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer.

Navigating first- and second-line treatment options in hormone receptor-positive HER2-negative advanced breast cancer.

Navigating first- and second-line treatment options in hormone receptor-positive HER2-negative advanced breast cancer.

Navigating first- and second-line treatment options in HR+HER2-negative advanced breast cancer.

Navigating first- and second-line treatment options in HR+HER2-negative advanced breast cancer.

Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer.

Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer.

Real-world clinical outcomes of intermediate-risk PAM50 (i-ROR) in HR+/HER2- early breast cancer and eligibility for adjuvant CDK4/6 inhibitors.

Real-world clinical outcomes of intermediate-risk PAM50 (i-ROR) in HR+/HER2- early breast cancer and eligibility for adjuvant CDK4/6 inhibitors.

Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trial.

Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trial.

Analysis of UGT1A1 germline variants in patients with advanced breast cancer treated with trastuzumab-deruxtecan: results from the PROCURE Project.

Analysis of UGT1A1 germline variants in patients with advanced breast cancer treated with trastuzumab-deruxtecan: results from the PROCURE Project.

Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 - metastatic breast cancer: A translational analysis of the GEICAM/2013-02 PEARL trial.

Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 - metastatic breast cancer: A translational analysis of the GEICAM/2013-02 PEARL trial.